Table 5.
ComD1 | ComD2 | |||||
---|---|---|---|---|---|---|
Peptide Number | Peptide Name | Sequence | IC50 (nM)b | 95% CIc | IC50 (nM)b | 95% CIc |
33 | CSP2-E1AI4Nvad10 | AMRNvaSRIILdFLFLRKK | >1000 | -- | 42.2 | 34.1–52.0 |
34 | CSP2-E1AI4Nled10 | AMRNleSRIILdFLFLRKK | >1000 | -- | 79.1 | 74.7–84.0 |
35 | CSP2-E1AI4HLeud10 | AMRhLeuSRIILdFLFLRKK | >1000 | -- | 97.6 | 62.3–151 |
36 | CSP2-E1AI4NvaI8FL9RF13LL14Q | AMRNvaSRIFRDFLLQRKK | >1000 | -- | >1000 | — |
37 | CSP2-E1AI4NvaI8FL9Rd10F13LL14Q | AMRNvaSRIFRdFLLQRKK | --d | -- | 229 | 89.7–585 |
See experimental section for detail of reporter strains. See supporting information for methods and plots of antagonism dose response curves. All assays were performed in triplicates.
IC50 values were determined by testing peptides over a range of concentrations.
95% confidence interval.
IC50 not determined due to the analog’s low activity in primary antagonism screening assay.